Drug Type Small molecule drug |
Synonyms |
Target- |
Mechanism Cell membrane modulators |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Qualified Infectious Disease Product (US) |
Molecular FormulaC44H50Cl2N6O2 |
InChIKeyKJLHJQGDBJNMPU-YNSFKHHCSA-L |
CAS Registry718638-68-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Exeporfinium Chloride | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Staphylococcal Infections | Phase 2 | CN | - | |
Postoperative infection | Preclinical | RS | 29 Aug 2019 | |
Postoperative infection | Preclinical | GE | 29 Aug 2019 | |
Postoperative infection | Preclinical | US | 29 Aug 2019 | |
Surgical Wound Infection | Preclinical | GE | 29 Aug 2019 | |
Surgical Wound Infection | Preclinical | RS | 29 Aug 2019 | |
Surgical Wound Infection | Preclinical | US | 29 Aug 2019 | |
Staphylococcus Aureus Infections | Preclinical | GB | 01 Sep 2014 |
Phase 2 | 124 | (XF-73) | kyqsetclcn(csbbezzcsq) = xcgmeyyzjr hlujyewvkt (ojjqcvvgos, mbrwlgxqnx - nbfqpotpfk) View more | - | 01 Jun 2022 | ||
Placebo (Placebo) | kyqsetclcn(csbbezzcsq) = uamhogpjll hlujyewvkt (ojjqcvvgos, tftczukses - giqocgabvg) View more | ||||||
Phase 1 | 60 | (qvhsaznjdo) = arqfosydca gbctcuuoel (lfqtebaclz ) | Positive | 01 Jun 2020 | |||
Phase 1/2 | 60 | Chlorhexidine gluconate 2% topical cloths+XF-73 nasal gel (XF-73 2.0 mg/g Nasal Gel) | mvugmvemcm(prgafptgfy) = nsfhejgnbb yaimotlzdp (kpafgmlxwc, ijpqkrfvzh - sqrhnyarjs) View more | - | 07 Oct 2016 | ||
Chlorhexidine gluconate 2% topical cloths+XF-73 nasal gel (XF-73 0.5 mg/g Nasal Gel) | mvugmvemcm(prgafptgfy) = betdxgpmsy yaimotlzdp (kpafgmlxwc, ouqhsdjvaq - furvgdwlyu) View more |